Foamix’s Nano-Emulsion Foam Fights Acne
The U.S. market for branded prescription drugs for acne was estimated to be approximately $2.6 billion for the 12 months ended March 31, 2014, of which $1.6 billion was attributed to topical drugs such as Epiduo and Aczone and $1 billion was attributed to oral drugs. Orally administered Solodyn is the brand name for an antibiotic called minocycline which is the current standard of care for moderate-to-severe acne. One company, Foamix, has developed a nano-emulsion foam that can be used to administer minocycline topically with greater effectiveness and fewer side effects.
Founded in 2003, Israeli company Foamix is looking to address the dermatology industry with a unique nano-emulsion drug delivery technology that is suitable for any drug and that can penetrate the skin safely with improved solubility and enhanced bioavailability. The Company recently filed for an IPO to raise around $60 million. Foamix has taken in just over $14 million in revenues from licensee agreements since inception, and has a deficit of just over $6 million. The Company has 54 granted patents worldwide, including 19 issued patents in the United States. Additionally, the company has more than 135 pending patent applications worldwide, of which over 70 applications are filed in the U.S.
Fighting Acne with FMX101
Here at Nanalyze, we invest the majority of our savings in 30 dividend-paying stocks that increase our income every year and outperform during both bull and bear markets. Find out which ones in the Quantigence report freely available to Nanalyze subscribers.